Danicopan

达尼可泮

Report date: 2024/07/02 17:18:36
NME

Base Information

Drug NameDanicopan
Drug Alias NameVoydeyaVOYDEYAACH-4471ACH-0144471ALXN-2040 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement factor D inhibitors
TargetsComplement factor D
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)C3 glomerulopathyHemolysis +[7] 
Global Approved IndicationsHemoglobinuria, Paroxysmal
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2024/01/18
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAchillion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlexion Europe SasAstrazeneca PlcAlexion Pharmaceuticals Inc +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)HemolysisHemoglobinuria, Paroxysmal
Inactive IndicationsC3 glomerulopathyGlomerulonephritis, MembranoproliferativeGeographic Atrophy +[4] 

Other Information

ATC CodeL04AJ09
Related LinksDrugBankKEGG